We report the design and synthesis of new conjugates (H2L1-4) consisting of a bifunctional bis(thiosemicarbazone) chelator conjugated to prostate-specific membrane antigen pharmacophores. Radiolabeling H2L1-4 with the 99mTc nitrido core in a one-pot synthesis at 95 °C for 10 min produced the complexes 99mTcTcN(L1-4) with high radiochemical purity (RCP > 95%) and excellent stability. In vitro evaluation of the 99mTcTc PSMA complexes demonstrated high cell-surface receptor binding and internalization in cancer cells expressing PSMA (PSMA+), which was inhibited by an excess of a PSMA-specific inhibitor. The most lipophilic of the complexes, 99mTcTcN(L2), also showed significant nonspecific uptake in the control cell line (PSMA-). SPECT-CT imaging of the four complexes, at 1 and 4 h postinjection and biodistribution studies at 5 h postinjection in BALB/c nude mice with both PSMA+ and PSMA- tumors, demonstrated significant differences in the receptor-specific tumor uptake and clearance pathways. 99mTcTcN(L3) and the bivalent 99mTcTcN(L4) showed predominantly renal clearance and the highest PSMA+ tumor uptake and retention. Conversely, 99mTcTcN(L1) and 99mTcTcN(L2) displayed gastrointestinal clearance and lower PSMA+ tumor uptake. The work demonstrates that bis(thiosemicarbazones) are effective bifunctional chelators for the development of 99mTc radiopharmaceuticals targeting PSMA with the potential to be easily modified to target other diseases.
Maclean et al. (2026) studied this question.